---
document_datetime: 2024-07-10 16:22:35
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pixuvri-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: pixuvri-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.8019709
conversion_datetime: 2025-12-20 02:19:47.229495
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0050               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 09/11/2021                                  |                                             | PL                               |           |
| IA/0049              | A.7 - Administrative change - Deletion of manufacturing sites                                    | 09/01/2020                                  | 18/12/2020                                  | Annex II and PL                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

Pixuvri Procedural steps taken and scientific information after the authorisation Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/9261/ 201905   | Periodic Safety Update EU Single assessment - pixantrone           | 28/11/2019   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|----------------------|--------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| T/0048               | Transfer of Marketing Authorisation                                | 29/08/2019   | 08/10/2019 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| R/0046               | Renewal of the marketing authorisation.                            | 28/03/2019   | 06/06/2019 | SmPC, Annex II and PL  | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated. Furthermore, the CHMP considered that, as all Specific Obligations have been fulfilled, there are no remaining grounds for the marketing authorisations to remain conditional and therefore recommends the granting of the MA no longer subject to Specific Obligations for Pixuvri. longer authorised |
| T/0045               | Transfer of Marketing Authorisation                                | 13/12/2018   | 18/02/2019 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| PSUSA/9261/ 201805   | Periodic Safety Update EU Single assessment - pixantrone product   | 29/11/2018   | n/a no     |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| PSUSA/9261/ 201711   | Periodic Safety Update EU Single assessment - pixantrone Medicinal | 28/06/2018   | 23/08/2018 |                        | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/9261/201711.                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| R/0042               | Renewal of the marketing authorisation.                            | 25/01/2018   | 23/03/2018 |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| PSUSA/9261/          | Periodic Safety Update EU Single assessment -                      | 14/12/2017   | 21/03/2018 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| 201705             | pixantrone                                                                                                                                                                                                            |                |                                   | the variation to terms of the Marketing Authorisation(s)' for PSUSA/9261/201705.   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-----------------------------------|------------------------------------------------------------------------------------|
| II/0040            | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                   | 07/12/2017     | n/a                               |                                                                                    |
| IA/0041            | B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) | 30/10/2017     | n/a                               | authorised                                                                         |
| PSUSA/9261/ 201611 | Periodic Safety Update EU Single assessment - pixantrone                                                                                                                                                              | 09/06/2017 n/a | longer                            | PRAC Recommendation - maintenance                                                  |
| N/0038             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) product                                                                                                              | 08/05/2017 no  | 21/03/2018 PL                     |                                                                                    |
| R/0034             | Renewal of the marketing authorisation.                                                                                                                                                                               | 26/01/2017     | 22/03/2017 SmPC, Labelling and PL |                                                                                    |
| IA/0037            | B.I.d.1.b.1 - Stability of AS - Change in the storage conditions - Change to more restrictive storage conditions of the AS Medicinal                                                                                  | 20/03/2017     | n/a                               |                                                                                    |
| IB/0035            | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                             | 15/12/2016     | n/a                               |                                                                                    |
| II/0032/G          | This was an application for a group of variations.                                                                                                                                                                    | 15/12/2016     | n/a                               |                                                                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/9261/ 201605   | Periodic Safety Update EU Single assessment - pixantrone                                                                                                                                                                                                                                                                                                                            | 01/12/2016   | n/a        |                       | PRAC Recommendation - maintenance                                                                               |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------|
| IAIN/0033/G          | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 28/11/2016   | 22/03/2017 | Annex II and PL       | authorised                                                                                                      |
| IA/0031              | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                        | 14/09/2016   | n/a no     | longer                |                                                                                                                 |
| IA/0029              | B.I.d.1.b.1 - Stability of AS - Change in the storage conditions - Change to more restrictive storage conditions of the AS product                                                                                                                                                                                                                                                  | 24/08/2016   | n/a        |                       |                                                                                                                 |
| IB/0030              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation Medicinal                                                                                                                                                                                                                             | 22/08/2016   | 22/03/2017 | Annex II              |                                                                                                                 |
| PSUSA/9261/ 201511   | Periodic Safety Update EU Single assessment - pixantrone                                                                                                                                                                                                                                                                                                                            | 09/06/2016   | n/a        |                       | PRAC Recommendation - maintenance                                                                               |
| R/0025               | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                             | 28/01/2016   | 22/03/2016 | SmPC, Annex II and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                          |                | having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Pixuvri, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion. authorised   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0026          | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                      | 11/12/2015               | n/a            |                                                                                                                                                                                                                                                                                                                                                                                |
| PSUSA/9261/ 201505 | Periodic Safety Update EU Single assessment - pixantrone                                                                                                                                                                                                                                                                                                                                                                                                                | 03/12/2015 21/08/2015 no | n/a n/a longer | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                              |
| IA/0024/G          | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure Medicinal product | 11/06/2015               | n/a            | PRAC Recommendation -                                                                                                                                                                                                                                                                                                                                                          |
| PSUSA/9261/ 201411 | Periodic Safety Update EU Single assessment - pixantrone                                                                                                                                                                                                                                                                                                                                                                                                                |                          |                | maintenance                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0022            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder                                                                                                                                                                                                                                                                                                                                                                     | 09/04/2015               | n/a            |                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|           | or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                         |            |               |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0020    | Renewal of the marketing authorisation.                                                                                                                                          | 22/01/2015 | 23/03/2015    | Annex II    | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Pixuvri, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion. longer authorised |
| PSUV/0018 | Periodic Safety Update                                                                                                                                                           | 04/12/2014 | n/a           |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| N/0019    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) product                                                                         | 20/10/2014 | 23/03/2015 no | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| PSUV/0015 | Periodic Safety Update                                                                                                                                                           | 26/06/2014 | 01/09/2014    | SmPC and PL | Please refer to Pixuvri (EMEA/H/C/2055/PSUV/0015) EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation                                                                                                                                                                                                                                                                                                                                   |
| IB/0017   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data Medicinal | 10/07/2014 | n/a           |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0016   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                        | 12/06/2014 | 01/09/2014    | SmPC        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| R/0014    | Renewal of the marketing authorisation.                                                                                                                           | 20/02/2014   | 10/04/2014    | The CHMP, having reviewed the available information on   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|----------------------------------------------------------|
| IAIN/0013 | B.IV.1.b - Change of a measuring or administration device - Deletion of a device                                                                                  | 16/12/2013   | 10/04/2014    | PL authorised                                            |
| IA/0012   | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                    | 04/10/2013   | n/a           | longer                                                   |
| IB/0009   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) product                 | 01/10/2013   | 10/04/2014 no |                                                          |
| IB/0011   | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                           | 20/08/2013   | n/a           |                                                          |
| IB/0010   | B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation Medicinal                                       | 08/08/2013   | n/a           |                                                          |
| IB/0008   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time | 08/08/2013   | n/a           |                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |               |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0006     | The MAH applied to update section 4.4 of the SmPC with regards to the photosensitivity statement following the EMA conclusion to the assessment of the Follow-up Measure MEA002 - In vivo phototoxicity study to further investigate the phototoxic potential of Pixuvri. C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH | 01/07/2013 | 10/04/2014    | SmPC                             | longer authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IAIN/0007/G | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release product                                                                                                                                                                                                                                                                              | 14/06/2013 | 10/04/2014 no | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| R/0005      | Renewal of the marketing authorisation. Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 17/01/2013 | 22/03/2013    | Annex II and PL                  | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Pixuvri, subject to the Specific Obligations and Conditions as laid down in Annex II |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                        |            |            |        | to the Opinion.   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------|-------------------|
| IB/0003 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                              | 10/07/2012 | 29/10/2012 | SmPC   |                   |
| IB/0004 | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                | 04/07/2012 | n/a        |        | authorised        |
| IB/0002 | B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation                                                      | 04/07/2012 | n/a        | longer |                   |
| IB/0001 | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data | 04/07/2012 | n/a no     |        |                   |

Medicinal product no longer authorised